THERE WAS a triumphal note as media across the country reported the rejection of Johnson & Johnson's claim for a secondary patent on its tuberculosis drug bedaquiline. It was big news in March when the Indian Patent Office rejected the claim, because bedaquiline is the most efficacious in treating life-threatening cases of drug-resistant TB. It is a medicine that is taken orally, has fewer of the lethal side effects of the older line of drugs and is desperately sought by patients. As a country that is burdened with the largest number of TB cases, and carries an additional load of more than a quarter of the world's drug-resistant cases, India badly needs access to generics medicines that are FEAT inexpensive and available in sufficient quantities. Bedaquiline, a patented medicine made by J&Jowned Janssen Pharmaceuticals, is neither. It is costly and hard to come by.
The original patent on bedaquiline expires in July this year, but J&J had sought to extend its monopoly with a patent for a fumarate salt version of the TB medicine. The claim was opposed in 2019 by two TB patient-activists, Nandita Venkatesan of Mumbai and Phumeza Tisile of South Africa, who were supported by humanitarian organisation Médecins Sans Frontières. The Patent Office upheld their challenge since India's law, specifically Section 3d, does not permit the patenting of incremental improvements on an existing drug unless there is proven improvement in efficacy. The rejection of the secondary patent on bedaquiline means the original patent expiry term stands, allowing generic versions to come into the market in a few months' time. The generic drugs are expected to cut costs as they generally do. J&J charges 27,000 for the prescribed six-month treatment.
There is hope, too, of supplies increasing significantly in the near future as reports talk of some companies launching their generic versions as early as August.
This story is from the April 16, 2023 edition of Down To Earth.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the April 16, 2023 edition of Down To Earth.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
The Pill That's Roiling US Drug Regulation
The hard right is challenging FDA's authority to regulate drugs with its lawsuit to ban America's most used abortion pill
TURN OVER A NEW LEAF
The young leaves of pilkhan free are a worthy alternative to leafy vegetables in the spring season
FAIR PRICE
Using a calculator, Uttar Pradesh scientifically fixes fee for transporting faecal sludge to treatment plants
THE FOREVER POLLUTANT
From production to usage to disposal, plastic is a threat to those who come in its contact SIDDHARTH GHANSHYAM SINGH
Seeds from the past
For a decade,200 villages in Odisha have conserved and grown 190 indigenous rice and millet varieties with proven climate resilience
TESTING TIMES
While the world is trying to identify uniform tests to measure soil biodiversity, it still needs investment and infrastructure to make them available to all
BREAKING NEW GROUND
Soil health is typically measured by its nutrient content, by presence of elements like nitrogen and phosphorus. No country in the world measures it in terms of soil biodiversity-a counting of underground faunal populations and microorganisms.
PRIME TRIGGER
Heat stress dominates debate on the causes of a mysterious chronic kidney disease that continues to baffle health experts and is on the rise globally
Coral catastrophe
Consistent ocean heating puts global corals at risk of mass bleaching in 2024
CHIPKO A DISTANT MEMORY
Whenever a dictionary of green terms is written, no matter in what language, it will contain at least one Hindi word-Chipko, which means to hug.
